Key Highlights
- French pharmaceutical company Servier will acquire Day One Biopharmaceuticals (DAWN) at $21.50 per share in a cash transaction valued at approximately $2.5 billion
- The acquisition price reflects a ~68% premium over Thursday’s closing price and 86% above the 30-day volume-weighted average
- Shares of DAWN jumped ~66% during premarket hours on March 6, 2026, following the buyout announcement
- Day One’s leadership team unanimously endorsed the transaction and urged stockholders to tender their shares
- Deal completion is anticipated in the second quarter of 2026, contingent upon regulatory approval and majority shareholder acceptance
French pharmaceutical powerhouse Servier has struck a deal to purchase Day One Biopharmaceuticals (DAWN) in an all-cash transaction totaling approximately $2.5 billion. Following the March 6 announcement, DAWN shares skyrocketed roughly 66% before regular market hours opened on Friday.
https://x.com/FenwickWest/status/2029944210065969265?s=20
Servier has committed to paying $21.50 for each outstanding Day One share. This valuation represents a 68% markup from Thursday’s final trading price and sits 86% higher than the stock’s 30-day volume-weighted average.
Day One Biopharmaceuticals, Inc., DAWN
Notably, the agreement doesn’t include a financing contingency, eliminating a frequent hurdle that can derail merger agreements. The parties anticipate finalizing the purchase during Q2 2026, subject to U.S. regulatory clearance and majority shareholder participation in the tender offer.
Day One’s leadership conducted a comprehensive evaluation of the proposal and unanimously voted to encourage shareholders to accept the tender. Standard deal protection mechanisms are in place, including a $87.7 million termination fee payable under specific circumstances if the acquisition doesn’t materialize.
Market observers weren’t entirely blindsided by Friday’s news. DAWN shares had already gained ground on Wednesday after acquisition rumors surfaced, with Jazz Pharmaceuticals (JAZZ) and Ipsen (IPSEY) mentioned as potential bidders at that time.
Strategic Rationale Behind the Acquisition
The cornerstone of this transaction is Day One’s primary asset, tovorafenib, a therapy designed for low-grade glioma treatment — a brain tumor variant. This compound holds special significance in childhood cancer care, which represents Day One’s core area of specialization.
For Servier, this purchase strengthens its position in rare cancer treatments. The French pharmaceutical enterprise, which generated €6.9 billion in revenue during fiscal year 2024/25, currently allocates nearly 20% of its branded product revenue toward research and development initiatives. Incorporating Day One’s portfolio aligns with Servier’s strategic objective of expanding its presence in precision oncology.
Transaction Mechanics
The acquisition follows a two-step process: an initial all-cash tender offer, followed by a merger once all conditions are satisfied. The absence of a financing requirement from Servier signals strong deal conviction and reduces execution risk.
The termination fee of $87.7 million offers Day One shareholders some protection if the deal fails to materialize under certain scenarios.
Before the acquisition announcement, Wall Street analysts had established a $17.00 price target on DAWN with a Buy recommendation — significantly lower than the $21.50 buyout price.
Day One’s market capitalization before the deal news was roughly $1.35 billion. The $2.5 billion transaction value demonstrates the substantial premium Servier is willing to pay for access to Day One’s drug pipeline.
Day One operates from its headquarters in Brisbane, California. Upon successful completion, the acquisition will transfer complete ownership to Servier, a privately-held French pharmaceutical organization with a commercial footprint spanning over 130 nations.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
